Optimizing therapy for vancomycin-resistant enterococci (VRE)

Seminars in Respiratory and Critical Care Medicine

Volumn 28, Issue 6, 2007, Pages 632-645

  Linden, Peter K ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antimicrobial resistance; Enterococcus; Linezolid; Nosocomial infection; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GLYCOPEPTIDE; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; METRONIDAZOLE; NOVOBIOCIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANEMIA; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL FLORA; BONE MARROW SUPPRESSION; DRUG COST; ENTEROCOCCAL INFECTION; FOREIGN BODY; GASTROINTESTINAL SYMPTOM; HUMAN; LACTIC ACIDOSIS; LEUKOPENIA; MYALGIA; OPTIC NERVE DISEASE; PERCUTANEOUS DRAINAGE; PERIPHERAL NEUROPATHY; PHLEBITIS; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SURGICAL DRAINAGE; THROMBOCYTOPENIA; UROGENITAL TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; WOUND INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; VANCOMYCIN;

EID: 37649017616     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996410     Document Type: Review

References (114)

1. Centers for Disease Control and Prevention. National Nosocomial Infection Surveillance (NNIS) system: report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-498
2. Wisplinghoff H, Bischoff T, Tallent SM, Seiferd H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-317
3. Moellering RC Jr. The Garrod Lecture. The Enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 1991;28:1-12
4. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46-65
5. Hodges TL, Zighelboim-Daum S, Eliopoulos GM, Wennersten C, Moellering RC Jr. Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother 1992;36:121-125
6. Hamilton-Miller JM, Purves D. Enterococci and antifolate antibiotics. Eur J Clin Microbiol 1986;5:391-394
7. LeClercq R, Couvalin P. Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991;35:1267-1272
8. Lefort A, Mainardi JL, Tod M, Lotholary O. Antienterococcal antibiotics. Med Clin North Am 2000;84:1471-1495
9. Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L. Penicillin- binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. J Infect Dis 1998;178:159-163
10. Grayson ML, Eliopoulos GM, Wennersten CB, et al. Increasing resistance to β-lactam antibiotics amongst clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother 1991;35:2180-2184
11. Horodniceanu T, Bougueleret L, El-Solh N, Bieth G, Delbos F. High level resistance to gentamicin in Streptococcus faecalis subsp. zymogenes. Antimicrob Agents Chemother 1979;16:686-689
12. Mederski-Samoraj BD, Murray BE. High level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis 1983;147:751-757
13. Spiegel CA, Hucyke M. Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance. Arch Intern Med 1989;149:1873-1875
14. Eliopoulos GM. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin North Am 1993;7:117-133
15. Leclercq R, Dutka-Malen S, Brisson-Noel A, et al. Resistance of enterococci to aminoglycosides and glycopeptides. Clin Infect Dis 1992;15:495-501
16. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-161
17. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States 1989-1993. MMWR Morb Mortal Wkly Rep. 1993;42:597-599
18. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among blood-stream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004;50:59-69
19. Lai KK, Fontecchio SA, Kelly AL, Baker S, Melvin ZS. The changing epidemiology of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2003;24:264-268
20. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006;42:S25-S34
21. Handwerger S, Skoble J. Identification of chromosomal mobile element conferring high-level vancomycin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1995;39:2446-2453
22. Gold HS. Vancomycin resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001;33:210-219
23. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-198
24. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin- resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-1347
25. Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus - New York. MMWR Morb Mortal Wkly Rep 2005;53:322-323
26. Miller D, Urdaneta V, Weltman A. Vancomycin-resistant Staphylococcusaureus - Pennsylvania 2002. MMWR Morb Mortal Wkly Rep 2002;51:902
27. Sievert DM, Boulton ML, Stolzman G, et al. Staphylococcus aureus resistant to vancomycin - United States 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-567
28. Whitener CJ, Park SY, Browne FA, et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004;38:1049-1055
29. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004;39:219-226
30. Beezhold DW, Slaughter S, Hayden MK, et al. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis 1997; 24:704-706
31. D'Agata EM, Gautam S, Green WK, Tang YW. High rate of false- negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin Infect Dis 2002;34:167-172
32. Weinstein JW, Tallapragada S, Farrel P, Dembry LM. Comparison of rectal and peri-rectal swabs for detection of colonization with vancomycin-resistant enterococci. J Clin Microbiol 1996;34:210-212
33. Montecalvo MA, Lencastre H, Carraher M, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995;16:680-685
34. Baden LR, Thiemke W, Skolnik A, et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance." Clin Infect Dis 2001;33:1654-1660
35. Roghmann MC, Aquiyumi S, Schwalbe R, Morris JG Jr. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1997;18:679-680
36. Tornieporth NG, Roberts RB, Hafner JJ, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case and control patients. Clin Infect Dis 1996;23:767-772
37. Bonten MJ, Hayden MK, Nathan C, et al. Epidemiology of colonization of patients and environment with vancomycin-resistant enterococci. Lancet 1996;348:1615-1619
38. Morris JG, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents including vancomycin, establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-259
39. Warren DK, Kollef MH, Seiler SM, Fridkin SK, Fraser VJ. The epidemiology of vancomycin-resistant Enterococcus in a medical intensive care unit. Infect Control Hosp Epidemiol 2003;24:257-263
40. Donskey CJ, Chowdhry T, Hecker M, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:1925-1932
41. Bonten MJ, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998;158:1127-1132
42. Linden P. Can enterococcal infections initiate sepsis syndrome? Curr Infect Dis Rep 2003;5:372-378
43. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-472
44. Kumar A, Robert D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596
45. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-155
46. Quale J, Landman D, Atwood E, et al. Experience with a hospital-wide outbreak of vancomycin-resistant enterococci. Am J Infect Control 1996;24:372-379
47. Lai KK. Treatment of vancomycin resistant Enterococcus faecium infections. Arch Intern Med 1996;156:2579-2584
48. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004;38:864-870
49. Finberg RW, Moellering RC, Tally FP, et al. The importance of bactericidal drugs, future directions in infectious diseases. Clin Infect Dis 2004;39:1314-1320
50. Tsigrelis C, Singh KV, Coutinho TD, Murray BE, Baddour LM. Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors. J Clin Microbiol 2007;45:631-635
51. Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin resistant ampicillin resistant Enterococcus faecium. Microb Drug Resist 1995;1:249-253
52. Dodge RA, Daly JS, Davaro R, Glew RH. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multi-drug resistant enterococci. Clin Infect Dis 1997;25:1269-1270
53. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342:710-721
54. Lautenbach E, Schuster MG, Biler WB, et al. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998;27:1259-1265
55. Gould CV, Fishman NO, Nakamkin NI, Lautenbach E. Chloramphenicol resistance in vancomycin resistant enterococcal bacteremia: impact of prior fluoroquinolone use. Infect Control Hosp Epidemiol 2004;25:138-145
56. Howe RA, Robson M, Oakhill A, et al. Successful use of tetracycline as therapy of an immunocompromised patient with septicemia caused by a vancomycin-resistant Enterococcus. J Antimicrob Chemother 1997;40:144-145
57. Linden PK, Pasculle AW, Manez R, et al. Utilization of novobiocin and ciprofloxacin for the treatment of serious infection due to vancomycin-resistant Enterococcus faecium. In: Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. Abstract 1027. Washington, DC: American Society for Microbiology; 1993:307
58. Montecalvo MA, Horowitz H, Wormser GP, et al. Effect of novobiocin containing antimicrobial regimens on infection and colonization with vancomycin resistant Enterococcus faecium. Antimicrob Agents Chemother 1995;39:794
59. Taylor SE, Paterson DL, Yu VL. Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium. Eur J Clin Microbiol Infect Dis 1998;17:798-800
60. Schmit JL. Efficacy of teicoplanin for enterococcal infections: 63 cases and review. Clin Infect Dis 1992;15:302-306
61. Aslangul E, Baptista M, Fantin B, et al. Selection of glycopeptide-resistant mutants of VanB type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis. J Infect Dis 1997;175:598-605
62. Hayden MK, Trenholme GM, Schultz JE, et al. In vivo development of teicoplanin resistance in a VanB Enterococcus faecalis. J Infect Dis 1993;167:1224-1227
63. Zhanel GG, Hoban DJ, Karlowsky JA. Nitrofurantoin is active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001;45:324-326
64. Linden P, Coley K, Kusne S. Bacteriologic efficacy of nitrofurantoin for the treatment of urinary tract infection due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1999;29:999
65. Cocito C, DiGiambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 2007;39(Suppl A):7-13
66. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004;38:92-98
67. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999;44:251-271
68. Linden PK, Moellering RC, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001;33:1816-1823
69. Brown J, Freeman BB. Combining quinupristin/dalfopristin with other agents for resistant infections. Ann Pharmacother 2004;38:677-685
70. Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant Enterococcus with quinupristin/dalfopristin and high dose-ampicillin. Ann Pharmacother 2004;38:989-91
71. Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. South Med J 2003;96:818-820
72. Raad I, Hachem R, Hanna H, et al. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001;45:3202-3204
73. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001;32:e83-e86
74. Werner G, Klare I, Spencker FB, Witte W. Intra-hospital dissemination of quinupristin-dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital. J Antimicrob Chemother 2003;52:113-115
75. Donabedian SM, Perri MB, Vager D, et al. Quinupristin-dalfopristin resistance in Enterococcus faecium isolates from humans, farm animals, and grocery store meat in the United States. J Clin Microbiol 2006;44:3361-3365
76. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-142
77. Pharmacia and Upjohn. Linezolid for the Treatment of Vancomycin Resistant Enterococcal Infections: A Double-Blind Trial Comparing 600 mg Linezolid Every 12 Hours with 200 mg Linezolid Every 12 Hours (study report M/1260/0054A). Peapack, NJ: Pharmacia Upjohn; 1999
78. Birmingham MC, Raynes CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant gram-positive infections: experience from a compassionate use program. Clin Infect Dis 2003;36:159-168
79. Stevens MP, Edmond MB. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005;41:1134-1142
80. Archuleta S, Murphy B, Keller MJ. Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection. Transpl Infect Dis 2004;6:117-119
81. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001;32:1373-1375
82. Zimmer SM, Caliendo AM, Thigpen MC, Somani J. Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis 2003;37:e29-e30
83. Tsigrelis C, Singh KV, Coutinho TD, Murray BE, Baddour LM. Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors. J Clin Microbiol 2007;45:631-635
84. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179
85. Seedat J, Zick G, Klare I, et al. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob Agents Chemother 2006;50:4217-4219
86. Marra AR, Major Y, Edmond MD. Central venous catheter colonization by linezolid-resistant, vancomycin-susceptible Enterococcus faecalis. J Clin Microbiol 2006;44:1915-1916
87. Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003;36:E146-148
88. Swaney SM, Shinabarger DL, Schaadt RD, Bock JH, Slightom JL, Zurenko GE. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA [abstract C-104]. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego. Washington, DC: American Society for Microbiology; 1998:98-99
89. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346:867-869
90. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002;46:3334-3336
91. Pai MP, Rodvold KA, Schreckenbefger PC, Gonezales RD, Petrolatti JM, Quinn JP. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;35:1269-1272
92. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 2001;285:1291
93. Halpern M. Linezolid-induced pancytopenia. Clin Infect Dis 2002;35:347-348
94. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clin Infect Dis 2002;34:1651-1652
95. Saijo T, Hayashi K, Yamada H, Wakakura M. Linezolid-induced optic neuropathy. Am J Ophthalmol 2005;139:1114-1116
96. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4:528-531
97. Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N Engl J Med 2003;348:86-87
98. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000
99. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of gram positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007;57:459-465
100. Jorgensen JH, Crawford SA, Kelly CC, Patterson JE. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 2003;47:3760-3763
101. Anastasiou DM, Thorne GM, Luperchio SA, Alder JD. In vitro activity of daptomycin against clinical isolates with reduced susceptibility to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006;28:385-388
102. Poutsiaka DD, Skiffingeron S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007;54:567-571
103. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006;26:347-352
104. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayop Clin Proc 2005;80:1215-1216
105. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005;41:565-566
106. Lewis JS II, Owens A, Cadena J, et al. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005;49:1664-1665
107. Green MR, Anasetti C, Sandin RL, Rolfe NE, Greene JN. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract 2006;12:179-181
108. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518-524
109. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005;52:181-186
110. Streit JM, Sader HS, Fritsche TR, Jones RN. Dalbabancin activity against selected populations of antimicrobial resistant gram-positive pathogens. Diagn Microbiol Infect Dis 2005;53:307-310
111. Barrett JF. Recent developments in glycopeptide antibacterials. Curr Opin Investig Drugs 2005;6:781-790
112. Baltch AL, Smith RP, Ritz WJ, Bopp LH. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY-333328 and ampicillin used singly and in combination against Enterococcus faecium. Antimicrob Agents Chemother 1998;42:2564-2568
113. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 Study. Antimicrob Agents Chemother 2006;50:862-867
114. Poulakou G, Giamarellou H. Investigational treatments for postoperative surgical site infections. Expert Opin Investig Drugs 2007;16:137-155